Search clinical trials for: relapsed/refractory PCNSL

Total 132 results

Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Primary Central Nervous System Lymphoma (PCNSL) | Secondary Central Nervous System Lymphoma (SCNSL)

United States
Senti Biosciences

Recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

AML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies

United States, Australia
The Children's Hospital of Zhejiang University...
College of Pharmaceutical Science at Zhejiang University

Recruiting

Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test

Acute Myeloid Leukemia in Children

China
Providence Health & Services

Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Primary Central Nervous System Lymphoma

United States
Massachusetts General Hospital
Pfizer

Recruiting

Elranatamab in R/R Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
The First Affiliated Hospital of Soochow University

Recruiting

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Acute Myeloid Leukemia (Relapsed/Refractory)

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

China
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

PCNSL

China
Cristiana Costa Chase, DO

Not yet recruiting

A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma (COSTA)

Relapsed/Refractory Multiple Myeloma

United States
IRCCS San Raffaele

Recruiting

Real World Data on Ibrutinib Use in PCNSL Rel/Ref (ReWIPretro)

PCNSL

Italy
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Tong Chen
Antengene Corporation

Recruiting

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Central Nervous System Lymphoma

China
Cellworks Group Inc.

Recruiting

myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports (myCare-102)

Cancer | Relapsed Cancer | Refractory Cancer

United States
The First Affiliated Hospital of Soochow University
The Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaborators

Recruiting

CAV Regimen for R/R Ph- B-ALL

Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
The Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaborators

Recruiting

CAV Regimen for R/R AML

Acute Myeloid Leukemia

China
University of Cologne
Incyte Corporation

Not yet recruiting

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL (MTR²)

Non-Hodgkin Lymphoma

Germany
Affiliated Hospital to Academy of Military Medical...

Recruiting

Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) (RMO)

Primary Central Nervous System Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Primary Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

China
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
National Research Center for Hematology, Russia

Recruiting

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Primary CNS Lymphoma

Russian Federation
Peking Union Medical College Hospital
Beijing Tiantan Hospital; Capital Medical University

Recruiting

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Primary Central Nervous System Lymphoma

China
Ruijin Hospital

Recruiting

Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Seoul National University Bundang Hospital
Samyang BioPharm

Recruiting

Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma (PCNSL-LEM)

Central Nervous System Lymphoma

Korea, Republic of
Hrain Biotechnology Co., Ltd.
Ruijin Hospital

Not yet recruiting

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Acute Lymphoblastic Leukemia

China
Fate Therapeutics

Recruiting

FT576 in Subjects With Multiple Myeloma

Multiple Myeloma | Myeloma

United States
Zhengzhou University

Recruiting

Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

PCNSL | Survival Analysis

China
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, United Kingdom, Netherlands
Asan Medical Center

Recruiting

Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System Lymphoma

Patients With Suspected or Diagnosed Central Nervous System Lymphoma

Korea, Republic of
IRCCS San Raffaele
Teresa Calimeri; Sara Steffanoni

Recruiting

Diagnosis; Objective RespOnse; THErApy (DOROTHEA)

Primary CNS Lymphoma

Italy
Huiqiang Huang
Guangdong 999 Brain Hospital

Not yet recruiting

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Non Hodgkin Lymphoma | PCNSL | Refractory and Relapsed Primary CNS Lymphoma

China
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Lakshmi Nayak, MD
Kazia Therapeutics Limited

Recruiting

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Primary Central Nervous System Lymphoma | Non-Hodgkin Lymphoma of Extranodal Site

United States
IRCCS Policlinico S. Matteo

Recruiting

Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis (DarPAL)

AL Amyloidosis

Italy
Miltenyi Biomedicine GmbH

Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

Central Nervous System Lymphoma | Transformed Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL) | Relapsed Diffuse Large B Cell Lymphoma

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Not yet recruiting

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Primary Central Nervous System Lymphoma (PCNSL)
Kim, Seok Jin
Celltrion; Samyang Biopharmaceuticals Corporation

Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)

Primary CNS Lymphoma

Korea, Republic of
European Hematology Association - Lymphoma Group
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Associazione...

Recruiting

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry (LUPIAE)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma

Spain, Netherlands, Italy, Croatia, Portugal, Ukraine
Huiqiang Huang
Xian-Janssen Pharmaceutical Ltd.; Nanfang Hospital of Southern Medical University and other collaborators

Recruiting

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Primary Central Nervous System Lymphoma | Non Hodgkin Lymphoma | PCNSL

China
Fudan University

Recruiting

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (Sincerely20)

Peripheral T-cell Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

PCNSL

China
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Primary Central Nervous System Lymphoma | Relapsed Cancer | Refractory Cancer | Recurrent Cancer

United States
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Nanchang University; RenJi Hospital; Ningbo... and other collaborators

Recruiting

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)

China
Peking Union Medical College Hospital
Peking University First Hospital; Beijing Tiantan Hospital; Chinese PLA General... and other collaborators

Recruiting

R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty (REMLA)

Primary Central Nervous System Lymphoma

China
Novartis Pharmaceuticals

Recruiting

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

Japan, Canada
Beijing Sanbo Brain Hospital

Recruiting

Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Primary Central Nervous System Lymphoma

China
Deok-Hwan Yang

Not yet recruiting

IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL

Primary Central Nervous System Lymphoma

Korea, Republic of
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary Central Nervous System Lymphoma

Denmark, Finland, Italy, Israel, Switzerland
Curis, Inc.

Recruiting

A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Relapsed Primary Central Nervous System Lymphoma | Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy | Refractory Primary Central Nervous System Lymphoma

United States, Spain, France, Czechia, Israel, Italy, Poland
Navy General Hospital, Beijing

Recruiting

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Primary Central Nervous System Lymphoma

China
Navy General Hospital, Beijing

Recruiting

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Primary Central Nervous System Lymphoma

China

Search clinical trials for: relapsed/refractory PCNSL

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations